About
Aurovir Pharma GmbH develops inhaled gold-ion (aurothioglucose) therapies targeting viral pulmonary infections and inflammatory lung diseases by leveraging the anti-inflammatory and antiviral properties of gold-based drugs.
Explore Aurovir Pharma GmbH's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.